Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Jazz Pharmaceuticals plc's quarterly P/E stands at 10.7x. EV/EBITDA has compressed 65.9% YoY to 8.7x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -38.47 | 10.67 | 12.72 | 8.08 | — | — | 9.90 | 8.14 | 10.72 | — | 21.65 | 15.12 | 20.39 |
| — | — | +28.5% | -0.8% | — | — | -54.3% | -46.1% | -47.4% | — | — | — | -71.2% | |
| P/S Ratio | 3.30 | 2.92 | 2.16 | 1.80 | 1.55 | 2.11 | 1.74 | 1.67 | 1.81 | 2.09 | 2.12 | 2.37 | 2.38 |
| — | +38.6% | +24.3% | +8.1% | -14.4% | +1.0% | -17.8% | -29.7% | -23.8% | -30.9% | -18.0% | +6.7% | -10.2% | |
| P/B Ratio | 3.17 | 2.76 | 2.40 | 2.05 | 1.75 | 1.81 | 1.85 | 1.69 | 1.97 | 2.04 | 2.29 | 2.64 | 2.59 |
| — | +52.0% | +29.8% | +21.5% | -11.3% | -11.0% | -19.3% | -36.2% | -23.6% | -37.1% | -29.6% | -13.2% | -16.4% | |
| P/FCF | 10.87 | 8.04 | 8.73 | 4.42 | 16.09 | 4.84 | 4.91 | 4.54 | 5.73 | 7.23 | 15.39 | 7.62 | 7.83 |
| — | +66.1% | +77.7% | -2.6% | +180.9% | -33.1% | -68.1% | -40.5% | -26.8% | -15.1% | +103.8% | +54.0% | -8.0% | |
| EV / EBITDA | 23.65 | 8.71 | 3.85 | 13.06 | — | 25.53 | 7.88 | 6.48 | 8.18 | 12.93 | 11.41 | 10.22 | 10.75 |
| — | -65.9% | -51.2% | +101.6% | — | +97.5% | -30.9% | -36.6% | -23.8% | -5.1% | — | -46.8% | -32.1% | |
| EV / EBIT | 80.77 | — | 14.18 | 53.43 | — | — | 12.39 | 10.59 | 14.87 | 28.23 | 13.70 | 19.85 | 21.62 |
| — | — | +14.5% | +404.5% | — | — | -9.6% | -46.6% | -31.2% | +37.1% | -2.4% | -11.9% | -9.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Jazz Pharmaceuticals plc's operating margin was 31.5% in Q1 2026, down 44.4 pp QoQ and up 37.7 pp YoY. The trailing four-quarter average of 11.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.2% | — | 97.9% | 77.1% | 88.9% | 88.3% | 88.2% | 89.4% | 89.3% | 89.4% | 89.4% | 89.5% | 89.8% |
| — | — | +11.1% | -13.8% | -0.4% | -1.2% | -1.4% | -0.1% | -0.6% | +4.5% | +8.0% | +4.3% | +3.6% | |
| Operating Margin | 5.3% | 31.5% | 75.9% | 5.1% | -65.6% | -6.2% | 17.5% | 24.7% | 19.5% | 7.3% | 12.1% | 17.7% | 16.5% |
| — | +605.9% | +332.9% | -79.3% | -437.0% | -184.8% | +44.8% | +39.1% | +18.3% | -48.0% | +144.7% | +573.6% | +79.6% | |
| Net Margin | -8.3% | 27.4% | 17.0% | 22.3% | -68.7% | -10.3% | 17.6% | 20.4% | 16.5% | -1.6% | 9.3% | 15.1% | 10.9% |
| — | +366.0% | -3.3% | +9.5% | -517.3% | -536.0% | +88.8% | +35.0% | +50.9% | -120.8% | +137.7% | +823.0% | +193.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | 6.6% | 4.9% | 6.6% | -18.2% | -2.2% | 4.6% | 5.4% | 4.5% | -0.4% | 2.6% | 4.2% | 3.0% |
| — | +395.9% | +6.3% | +21.0% | -503.4% | -469.1% | +77.5% | +29.5% | +48.5% | -118.2% | +131.7% | +733.4% | +199.0% | |
| ROA | -3.0% | 2.5% | 1.8% | 2.3% | -6.4% | -0.8% | 1.6% | 1.8% | 1.5% | -0.1% | 0.8% | 1.3% | 0.9% |
| — | +417.1% | +12.2% | +23.8% | -530.2% | -510.7% | +89.0% | +39.3% | +58.7% | -120.3% | +136.8% | +817.8% | +210.2% | |
| ROIC | 2.1% | 4.2% | 8.3% | 0.5% | -6.6% | -0.5% | 1.8% | 2.4% | 1.8% | 0.6% | 1.2% | 1.6% | 1.5% |
| — | +875.1% | +362.4% | -77.6% | -456.3% | -187.0% | +55.5% | +47.6% | +24.8% | -47.7% | +145.8% | +610.8% | +105.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Jazz Pharmaceuticals plc's Debt/EBITDA ratio is 3.2x, down from 5.8x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 39.6% YoY to 2.04x, tightening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.26 | 0.24 | 1.25 | 1.37 | 1.47 | 1.30 | 1.51 | 1.49 | 1.54 | 1.57 | 1.55 | 1.66 | 1.65 |
| — | -81.7% | -16.8% | -7.8% | -4.8% | -17.1% | -2.9% | -10.5% | -6.4% | -10.2% | -17.7% | -21.6% | -13.9% | |
| Debt / EBITDA | 7.08 | 3.20 | 5.79 | 23.03 | — | 49.73 | 17.16 | 14.58 | 15.98 | 25.20 | 20.56 | 17.30 | 18.28 |
| — | -93.6% | -66.2% | +58.0% | — | +97.4% | -16.6% | -15.7% | -12.6% | +22.9% | — | -48.4% | -27.7% | |
| Current Ratio | 1.86 | 2.04 | 1.86 | 1.65 | 1.62 | 3.38 | 4.46 | 4.26 | 2.37 | 2.27 | 2.24 | 2.06 | 3.18 |
| — | -39.6% | -58.3% | -61.3% | -31.6% | +49.0% | +99.4% | +106.6% | -25.7% | -26.0% | -19.9% | -34.8% | -13.3% | |
| Quick Ratio | 1.67 | 1.85 | 1.67 | 1.44 | 1.37 | 2.97 | 3.99 | 3.74 | 2.02 | 1.90 | 1.85 | 1.67 | 2.49 |
| — | -37.9% | -58.1% | -61.5% | -31.9% | +56.8% | +116.3% | +123.3% | -18.9% | -18.3% | -8.9% | -26.2% | +1.5% | |
| Interest Coverage | -2.22 | 8.44 | 5.59 | 1.19 | -14.53 | -0.48 | 4.46 | 4.43 | 3.22 | 1.59 | 3.34 | 2.41 | 2.15 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into JAZZ consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JAZZ stock.
Jazz Pharmaceuticals plc's current P/E is -38.5x. The average P/E over the last 3 quarters is 10.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Jazz Pharmaceuticals plc's current operating margin is 5.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Jazz Pharmaceuticals plc's business trajectory between earnings reports.